866-997-4948(US-Canada Toll Free)

Victoza (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Jul 2013

Category :

Metabolic Disorders

No. of Pages : 49 Pages


GlobalData has released its new report, Victoza (Type 2 Diabetes) Forecast and Market Analysis to 2022. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Victoza (liraglutide) was developed by Novo Nordisk; it was approved by the EMA in 2009 and by the FDA in 2010.

Scope

  • Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Victoza including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Victoza for the top ten countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Victoza performance
  • Obtain sales forecast for Victoza from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China)
Table of Contents

1 Table of Contents

1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10

3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis 15
3.1.4 Quality of Life 16
3.2 Symptoms 16

4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Diagnosis and Referrals 18
4.1.2 Treatment Guidelines 19

5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26

6 Victoza (liraglutide) 28
6.1 Overview 28
6.2 Efficacy 29
6.3 Non-glycemic Benefits 30
6.4 Safety 30
6.5 SWOT Analysis 31
6.6 Forecast 32

7 Appendix 33
7.1 Bibliography 33
7.2 Abbreviations 37
7.3 Methodology 40
7.4 Forecasting Methodology 40
7.4.1 Diagnosed Type 2 Patients 40
7.4.2 Percent Drug-Treated Patients 41
7.4.3 Drugs Included in Each Therapeutic Class 41
7.4.4 General Pricing Assumptions 42
7.4.5 Individual Drug Assumptions 43
7.4.6 Generic Erosion 43
7.5 Physicians and Specialists Included in this Study 44
7.6 About the Authors 46
7.6.1 Analyst II - CVMD 46
7.6.2 Therapy Director - CVMD and Infectious Disease 46
7.6.3 Global Head of Healthcare 47
7.7 About GlobalData 48
7.8 Disclaimer 48

List of Table


Table 1: Symptoms of Type 2 Diabetes 17
Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes 18
Table 3: Treatment Guidelines for Type 2 Diabetes 20
Table 4: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012 23
Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012 27
Table 6: Product Profile - Victoza 29
Table 7: Victoza SWOT Analysis, 2012 31
Table 8: Global Sales Forecasts ($m) for Victoza, 2012-2022 32
Table 9: Number of High-Prescribing Physicians Surveyed 45

List of Chart


Figure 1: ADA/EASD General Recommendations for Antihyperglycemic Therapy 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *